HF
MGX icon

HRT Financial’s Metagenomi Therapeutics MGX Stock Holding History

HRT Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Sell
10,674
-417
-4% -$648 ﹤0.01% 3609
2025
Q4 		$17K Sell
11,091
-3,006
-21% -$6.51K ﹤0.01% 3003
2025
Q3 		$33K Sell
14,097
-44,946
-76% -$91.2K ﹤0.01% 2649
2025
Q2 		$87K Buy
+59,043
New +$92.5K ﹤0.01% 2227
2024
Q2 		– Sell
-31,477
Closed -$332K – 3258
2024
Q1 		$332K Buy
+31,477
New +$362K ﹤0.01% 1497

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's MGX Position: Q1 2026 in Review

HRT Financial reduced its Metagenomi Therapeutics (MGX) stake by 3.8% in Q1 2026, selling an estimated $648 and leaving 10,674 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3609.

HRT Financial first reported a position in MGX in Q1 2024 and has held it in 5 quarters since. The position peaked at $332K in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • HRT Financial held 10,674 shares of Metagenomi Therapeutics worth $14K as of Q1 2026.
  • HRT Financial sold 417 Metagenomi Therapeutics shares in Q1 2026, an estimated $648.
  • Metagenomi Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3609 holding.
  • HRT Financial first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • HRT Financial's Metagenomi Therapeutics position peaked at $332K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.